The present invention relates to herpes viral mutants and methods of using these
viral mutants for selectively targeting tumor cells or other populations of target
cells. The viral mutants of the invention are capable of selective targeting due
to the use of tumor-specific and/or cell-specific promoters to drive expression
of the herpes 34.5 gene.
